DBV Technologies (DBVT) Other Accumulated Expenses (2019 - 2026)
DBV Technologies (DBVT) posted quarterly Other Accumulated Expenses of $13.8 million for Q2 2026, up 83.56% year-on-year from $7.5 million in Q2 2025, and up 27.78% on a QoQ basis from $10.8 million in Q1 2026.
DBV Technologies (DBVT) Other Accumulated Expenses (2019 - 2026) Analysis & Trends
DBV Technologies (DBVT) has reported Other Accumulated Expenses for 8 consecutive years, with $13.8 million the latest figure, recorded in Q2 2026.
- Quarterly Other Accumulated Expenses rose 83.56% year-over-year to $13.8 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $13.8 million (up 83.56% YoY) and the FY2025 annual result came in at $15.8 million, up 89.72% from the prior year.
- Other Accumulated Expenses rose to $13.8 million in Q2 2026 per DBVT's latest filing, from $10.8 million in the prior quarter.
- Over the last five years, Other Accumulated Expenses for DBVT reached as high as $15.8 million in Q4 2025 and fell as low as $5.0 million in Q1 2024.
- A 5-year average of $8.7 million and a median of $8.5 million in 2022 frame the typical range for Other Accumulated Expenses.
- Annual changes were most pronounced in 2022 — Other Accumulated Expenses sank 34.9% — and 2026, when it surged 98.27%.
- Year by year, Other Accumulated Expenses stood at $9.2 million in 2022, then fell by 3.0% to $8.9 million in 2023, then fell by 6.78% to $8.3 million in 2024, then surged by 89.72% to $15.8 million in 2025, then declined by 12.66% to $13.8 million in 2026.
- According to Business Quant data, Other Accumulated Expenses over the past three periods registered $13.8 million, $10.8 million, and $15.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | DBV Technologies | 267.50 Mn | 92.60 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 13.80 Mn |
| Mar 31, 2026 | 10.80 Mn |
| Dec 31, 2025 | 15.80 Mn |
| Sep 30, 2025 | 8.45 Mn |
| Jun 30, 2025 | 7.52 Mn |
| Mar 31, 2025 | 5.45 Mn |
| Dec 31, 2024 | 8.33 Mn |
| Sep 30, 2024 | 7.79 Mn |
| Jun 30, 2024 | 6.16 Mn |
| Mar 31, 2024 | 5.02 Mn |
| Dec 31, 2023 | 8.93 Mn |
| Sep 30, 2023 | 8.67 Mn |
| Jun 30, 2023 | 7.26 Mn |
| Mar 31, 2023 | 6.78 Mn |
| Dec 31, 2022 | 9.21 Mn |
| Sep 30, 2022 | 8.62 Mn |
| Jun 30, 2022 | 8.78 Mn |
| Mar 31, 2022 | 8.72 Mn |
| Dec 31, 2021 | 12.36 Mn |
| Sep 30, 2021 | 12.66 Mn |